TCON Stock Price, Chart, Stats & News

TRACON Pharmaceuticals, Inc. functions as a biopharmaceutical enterprise, primarily dedicated to the discovery, development, and eventual market launch of cancer treatments within the United States. Its current product pipeline features several assets in various stages of clinical trials. These include envafolimab (KN035), a PD-L1 single-domain antibody being investigated for the treatment of soft tissue sarcoma, and YH001, an experimental humanized CTLA-4 IgG1 monoclonal antibody targeting a range of cancer indications.